Assembly biosciences reports first quarter 2025 financial results and recent updates

– ongoing clinical studies for four candidates on track with data expected in 2025, including interim phase 1b data for long-acting helicase-primase inhibitors abi-5366 and abi-1179 anticipated in fall 2025 –
ASMB Ratings Summary
ASMB Quant Ranking